Pfizer (PFE) Tops Q1 EPS by 12c; Boosts FY16 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St falls as oil ticks up, yields rise ahead of US-China summit
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil holds near two-week lows while diesel cracks hit record
Pfizer (PFE) Target Increases at BMO Capital Following a Good Quarter
May 4, 2016 6:59 AM EDTBMO Capital analyst, Alex Arfaei, raised his PT on Pfizer (NYSE: PFE) to $40 (from $39) but admitted that much of the top-line beat was driven by more selling days in 1Q16 vs. 1Q15. Pfizers major growth drivers (e.g., Prevnar, Ibrance, Xeljanz, and Eliquis) all... More
